Skip to Content
  1. Authors
  2. Morningstar Fund Analysts

Morningstar Fund Analysts

Morningstar fund analysts cover more than 1,700 mutual funds and write regular commentary covering fund industry news, fund investing trends, picks, portfolio planning, international investing, and more.

Latest

The manager of Leuthold Asset Allocation, which has been reeling from outflows, has left the firm, prompting the merger. Also, AllianceBernstein changes named managers in its target-date series and target-risk suite, ING swaps out managers on its asset-allocation team supporting multiasset funds, and American Funds is set to launch an emerging-markets fund.

AllianceBernstein to buy W.P. Stewart, FPA Paramount alters its focus, Fidelity to roll out a short-duration high-yield fund, PIMCO plans for a managed-futures fund, and a sad farewell to retired T. Rowe Price manager and 1995 Fund Manager of the Year Jack Laporte.

The Fairholme Fund sues the federal government seeking dividends from its stakes in Fannie and Freddie, Munder Capital is on the block, a former Columbia manager succeeds Michael Kobs in the management of a set of Vanguard's municipal bond funds, and Columbia brings on board a former Putnam value equity manager.

TIAA-CREF and Henderson to start a new global real estate investment management company, Invesco High Yield Municipal opens back up to investors, Utah's Gold-rated 529 program cuts costs and adds funds from DFA, and Calamos seeks to begin issuing actively managed ETFs.

Vanguard launches international-bond fund, FPA Crescent picks up 2 new comanagers, and managers depart at GSAM, Buffalo, and BlackRock. Also, Matthews to close its Asia dividend fund, and Morgan Stanley set to launch a global quality stock fund.

Fairholme takes a big stake in Fannie and Freddie preferreds, a manager of a Bronze-rated Oppenheimer fund departs, Templeton Frontier Markets closes to new investors, a slew of manager changes at Bridgeway, and some high-profile Janus fund managers resurface at a hedge fund.

In a tough week for Marsico, the firm is removed as a subadvisor on two separate funds. Also, Calamos plans dividend and mid-growth funds, Oppenheimer to close Discovery to new investors, and John Hancock makes a raft of portfolio-management changes.

Bob Doll to take the helm of a Nuveen large-cap value fund, Gary Black to manage a new alts fund for Calamos, RiverPark drafts a new alts fund, and ALPS plans a tactical Asia-Pacific fund. Also, 3 new actively managed ETFs from PIMCO are ready for launch.

Brown Brothers Harriman launches a concentrated large-blend fund investing in U.S. and foreign stocks; Vanguard reopens its Capital Opportunity fund to individual investors; Franklin Templeton rolls out an emerging-markets bond fund; USAA seeks permission to create actively managed ETFs; and manager changes at Perkins and Calvert.

The conservative bank-loan fund manager plans to step away at the end of March. Also, DoubleLine recruits more professionals from TCW, Principal files for permission to market actively managed ETFs, T. Rowe Price nears launch of its world-allocation fund, Vanguard to merge away a Florida muni-bond fund, Vanguard Wellington reports lower fees, and a new small-cap fund from BlackRock.

Fidelity has more than doubled the number of commission-free iShares ETFs available through Fidelity's brokerage platform. Also, Joe Balestrino to leave Federated, a host of manager changes at Winslow Capital, Prudential cuts ties with Marsico, and fund closings at Touchstone and Prudential.

Harbor Capital Appreciation gets a new comanager, some Vanguard expense ratios fall, Oppenheimer changes a value manager, Vanguard rotates some bond fund managers, a Lord Abbett small-cap blend manager leaves, and more.

As part of Aberdeen's acquisition of Artio, some international fund managers to depart. Also, a management change on a T. Rowe Price health-care fund, Columbia hires Putnam's former asset-allocation head, and ClearBridge and Legg Mason Capital Management funds to merge.

Joyce is also set to leave GMO. Also, American Century's LIVESTRONG funds withstand Lance Armstrong controversy, Dreyfus' CEO departs, manager changes at Fidelity and American Century, and analyst reductions at UBS Global Asset Management.

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

  • Verify your identity, personalize the content you receive, or create and administer your account.
  • Provide specific products and services to you, such as portfolio management or data aggregation.
  • Develop and improve features of our offerings.
  • Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.